US Pharma MarketingBayer to make
Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson.
“We’re going to be careful, but also aggressive,” Anderson said on a first-quarter earnings call ...
Source: Endpoints News